Drs Iams and Shah discuss the process of diagnosing Lambert-Eaton myasthenic syndrome in neuroendocrine cancers, how the condition affects patient prognoses, and the primary goals of delivering coordinated care with in combination with cancer treatments.

Drs Bekaii-Saab, George, and von Mehren discuss key efficacy data and patient-reported outcomes from the INTRIGUE trial, the rationale for a phase 1/2 study investigating the novel ULK inhibitor DCC-3116 in patients with advanced or metastatic RAS or RAF–mutated solid tumors, and how vimiseltinib may alleviate unmet needs in the tenosynovial giant cell tumors population.

Dr Levy discusses the significance of the FDA approval of trastuzumab deruxtecan in HER2-mutant NSCLC, the pivotal efficacy and safety data from the DESTINY-Lung02 trial, and the optimal use of companion diagnostic tests in the field.

Dr Petrylak discusses current issues with genetic testing and disease management in prostate and bladder cancer, some of the reasons for poor testing rates, and the importance of proper multidisciplinary management during testing and when seeking to mitigate adverse effects.

Drs Goldberg and Sussman discuss key findings from their research on rates of gastrointestinal mortality, the factors that could contribute to these differences, and ways these disparities can be addressed.

Dr Berchuck discusses the effects of treatment intensification with darolutamide in men with metastatic hormone-sensitive prostate cancer, the significance of the approval of darolutamide plus docetaxel and androgen deprivation therapy, and lingering questions left unanswered by the pivotal ARASENS study.

Dr Katz discusses the implications of a recently published phase 2 study investigating neoadjuvant mFOLFIRINOX with or without hypofractionated radiation therapy results for patients with borderline resectable pancreatic ductal adenocarcinoma.

Drs Luger, Roboz, and Stock discuss the issues that were most prominent in leukemia treatment when they began their careers and what motivated them to continue to work toward progress in the field even when treatment outcomes were dismal. They also share their experiences with being women in their chosen career paths, such as how their gender has influenced their professional and personal decisions, as well as how they interact with and support other female colleagues.

Dr Gradishar emphasizes the importance of defining metastatic breast cancer subtypes, the implications of molecular testing and genetics on treatment decisions, and the need for honest and comprehensive patient-provider communication about therapeutic options and clinical trial opportunities throughout the course of disease.

Dr Subbiah discusses findings from 4 presentations that stood out to him from the 2022 ASCO Annual Meeting: phase 2 data (NCT04165772) demonstrating a 100% complete response rate in 12 patients with mismatch repair–deficient, locally advanced rectal cancer who received dostarlimab (Jemperli); DESTINY-Breast04 (NCT03734029), results he called “important and practice changing” for patients with HER2-low unresectable and/or metastatic breast cancer; a first-in-human study (NCT04585750) of PC14586, a novel agent targeting mutated TP53 in advanced solid tumors; and the LIBRETTO-001 trial (NCT03157128), which demonstrated that selpercatinib (Retevmo) can target RET-positive fusions in solid tumors.